The pharmacokinetics of prednisolone given intravenously were studied in 11 children with relapsed steroid responsive nephrotic syndrome, and four control subjects. The clearance of both total and unbound drug was decreased in these children and the unbound fraction of the drug in plasma was significantly correlated with the degree of hypoalbuminaemia. We conclude that changes in the clearance of prednisolone and altered protein binding might account for some of the variability in both therapeutic responses and the incidence of toxicity in patients treated with standard dosage regimens.
The introduction of glucocorticoid treatment of steroid responsive nephrotic syndrome reduced the mortality appreciably, but there was still considerable morbidity, with about one third of all patients having at least two relapses within six months of the initial episode. A further third continued to relapse less frequently, while the remainder had no relapses at all.' These differences in outcome have not been explained pathophysiologically, and there is a degree of prognostic variability despite treatment with standardised regimens of glucocorticoid drugs. Insufficient drug treatment might fail to suppress the disease adequately; on the other hand, Leisti and Koskomies found a strong association between severe hypothalamicpituitary-adrenal suppression and a high risk of early relapse. 2 The degree of hypothalamicpituitary-adrenal suppression is proportional to the dose of glucocorticoid in subjects who do not have nephrotic syndrome so that an excessive dose of glucocorticoids could predispose to early relapse. 3 The variable prognosis of steroid responsive nephrotic syndrome might be explained by variations in the way the body handles glucocorticoid drugs. There is considerable potential for pharmacokinetic variability both within and between patients. Glucocorticoids circulate bound to plasma albumin,4 transcortin,5 and al-acid glycoprotein,6 and it is thought that only the unbound drug is pharmacologically active. 4 Varying degrees of hypoproteinaemia always occur in steroid responsive nephrotic syndrome, and Lewis et al drew attention to the clinical importance of this by showing that there was an increased incidence of toxic effects of glucocorticoids in hypoalbuminaemic subjects. 7 The signs of cushingoid toxic effects vary among children with steroid responsive nephrotic syndrome, some patients developing severe complications while others are unaffected despite being given standard doses of prednisolone.
To examine the possibility that the variable prognosis of patients with steroid responsive nephrotic syndrome treated with prednisolone might be associated with changes in the pharmacokinetics of prednisolone, we have studied the kinetics of this drug given intravenously to children with acute nephrosis, using total and unbound plasma concentration times.
Patients and methods

STUDY DESIGN
Intravenous pharmacokinetic studies were performed on 11 children with relapses of steroid responsive nephrotic syndrome. Their median age was 10 years (range 4-16) and their median plasma albumin concentration was 23 g/l (range: 16-33 g/l) (table 1). Prednisolone was given as an intravenous bolus injection of prednisolone phosphate (Codelsol; Merk, Sharpe and Dohme) 30-64 mg (median: 60 mg). Ten 3 ml blood samples were taken through an indwelling intravenous cannula at 10, 15, 20, 25, 30, 60, 90, 120, 240, and 360 minutes after the injection of prednisolone. Patients were selected for the study because they were expected to be able to tolerate the experimental protocol and in addition, the patients or their parents, or both, had given consent. Ethical approval was given by Leeds Eastern District ethics committee.
Four volunteers aged 14-30 years who did not have nephrosis were also studied after having received a bolus injection of 60 mg of prednisolone. All had normal plasma albumin concentrations between 43-49 g/l (table 1) .
MEASUREMENT OF PLASMA PREDNISOLONE CONCENTRATIONS
Total prednisolone concentrations were measured by high performance liquid chromatography8 using a 30 cmx 3-9 mm inside diameter stainless steel 10 [tm porous silica column with a mobile phase consisting of dichloromethane: ethanol:water:glacial acetic acid (500:30:30:1% v/v) at a flow rate of 2 ml/min and ultraviolet detection at 254 nm. The interassay coefficient of variation was 5 3% (n=23) at 100 ng/ml and the limit of detection was 5 ng/ml.
Unbound prednisolone concentrations were measured after ultrafiltration.9 A sample of plasma (1 ml) was placed in a Centrifree ultrafiltration chamber (Amicon) and centrifuged at (13)) were treated as dependent variables, which were regressed on dose as a function of both surface area and body weight, body weight, surface area, plasma albumin concentration, and age of the subject. Only terms that were significant in the regression equation at the 5% level were subsequently used.
Results are given as mean (SD) and the significance of differences between groups were assessed by the Mann-Whitney U test. A probability of <0 05 was accepted as significant. Clearance and apparent volume of distribution are expressed in terms of body surface area to permit comparisons to be made between children with nephrosis and control subjects. Results Representative profiles of total and unbound prednisolone concentration times after a 60 mg/M2 intravenous dose of prednisolone are shown in fig 1 . Both curves are characterised by an initial rapid distribution phase (a) followed by a slower elimination phase (13) and this pattern was repeated in all subjects studied. Analysis of these data with the 'C-STRIP' programme showed that a biexponential equation was the best fit for each subject studied. The pharmacokinetic measurements of both total and unbound prednisolone in patients with nephrosis and volunteers are shown in tables 2 and 3, respectively, and each pharmacokinetic measurement is discussed below.
AREA UNDER THE CONCENTRATION TIME CURVE AND PLASMA CLEARANCE Tables 2 and 3 show that there was no difference between area under the concentration time curve for total concentration of the drug for patients with nephrosis and volunteers. Although the area under the concentration curve for the unbound drug was 84% greater in the group of patients with nephrosis compared 10 0001 Control children 50.7* (13-8)
2-1 (0-5) 'p>0-0l; **p>0-001 compared with value calculated for total prednisolone. increases. The latter explanation seems more patients with nephrosis the mean of the con-likely, because a significant inverse relationship itration averaged value of the percent of drug was found between the percentage of unbound bound was 50 (13)% (n=ll), and in volun-prednisolone and the plasma clearance of the rs it was 30 (7'0)% (n=4), though this differ-unbound drug in children with nephrosis. Total -e was not significant.
clearance would not change, because this mearhe variation in percentage of unbound surement is related to the unbound fraction and dnisolone and its correlation with plasma clearance of the unbound drug through the iumin concentration in patients with a relapse relationship: total clearance equals the unbound nephrosis is shown in fig 2. As expected the fraction multiplied by the clearance of the ationship between these two variables was unbound drug. Thus if the percentage of ,erse (r=-0-78; p<001), which suggests unbound prednisolone increased and clearance It as plasma albumin concentrations decrease, of the unbound drug decreased in proportion, re is a concomitant increase in the fraction of no change would be expected in total clearance. bound prednisolone. The intercept at zero Prednisolone is largely cleared by the liver umin concentration, gives a value for per-and the plasma clearance of unbound drug is a tage of unbound prednisolone of about 92%, measure of the intrinsic clearance by this organ. ich suggests that the bulk of prednisolone is Intrinsic clearance is dependent on the metaand to albumin in the range of doses tested in bolic activity of the liver and as clearance of the s study. There was no significant correlation unbound drug decreases with increasing -ween the percentage of unbound predniso-severity of hypoalbuminaemia, it seems likely e and total volume of distribution, volume of that the ability of the liver to eliminate predtribution of unbound drug, half life, and nisolone is impaired in children with active al clearance of the drug. 
